Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217082 · ClinicalTrials.gov registry record
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
A clinical trial of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 35
- Enrollment target
- 1
- Study location
NCT05217082 is a study of Multiple Myeloma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 35 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05217082, a study of Multiple Myeloma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Conditions Studied
Study Locations (1)
North Carolina
- Local Institution - 0001 - Morrisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-02-22 |
| Est. Completion | 2022-08-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05217082
The ClinicalTrials.gov registry entry for NCT05217082 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT05217082 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05217082 about?
NCT05217082 is a clinical study titled "A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure". The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
What is the current status of trial NCT05217082?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2022-02-22. Estimated completion is 2022-08-03.
What conditions does trial NCT05217082 study?
This clinical trial studies the following conditions: Multiple Myeloma.
Who is sponsoring clinical trial NCT05217082?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05217082 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.